![Pearls in a shell](/media/hbmpartners/styles/hero_small/public/images/hero-images/hero-portfolio-companies.jpg?h=14832055&itok=DIQpNLis)
ArriVent Biopharma
Industry
Oncology
Website
HBM contact
Company status
Public
Arrivent acquired rights for furmonertinib, an EGFR TKI approved in China, which they are developing in an exon-20 mutant NSCLC patient global Phase 3 registrational trial.
![Logo ArriVent Biopharma](/media/hbmpartners/images/portfolio/logo/arrivent.png)